Phase 3 Clinical Trials With Primary Completion Dates in March 2026
This is a list of Phase 3 trials with primary completion dates in March 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | 2026-03-01 | Phase 3 | NCT06828861 | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial |
| ALMRY | Almirall SA | 2026-03-01 | Phase 3 | NCT05916365 | Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2026-03-01 | Phase 3 | NCT06747468 | Avexitide for Treatment of Post-Bariatric Hypoglycemia |
| CING | Cingulate Inc. | 2026-03-01 | Phase 3 | NCT05924594 | Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 |
| IMVT | Immunovant, Inc. | 2026-03-01 | Phase 3 | NCT05524571 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| IVVD | Invivyd, Inc. | 2026-03-01 | Phase 3 | NCT07298434 | Study of VYD2311 for the Prevention of COVID-19 |
| KPTI | Karyopharm Therapeutics Inc. | 2026-03-01 | Phase 3 | NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma |
| KPTI | Karyopharm Therapeutics Inc. | 2026-03-01 | Phase 3 | NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis |
| VRDN | Viridian Therapeutics, Inc. | 2026-03-01 | Phase 3 | NCT06625411 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) |